Created at	Source	Raw Value	Validated value
Sept. 10, 2022, 12:30 a.m.	usa	Part A: Changes of the immunogenicity against Wuhan;Part B: Changes of the immunogenicity against Omicron BA.1;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose	Part A: Changes of the immunogenicity against Wuhan;Part B: Changes of the immunogenicity against Omicron BA.1;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose;Safety and tolerability of PHH-1V as third or fourth dose
Dec. 3, 2021, 11:30 p.m.	usa	Changes of the immunogenicity against Wuham;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V	Changes of the immunogenicity against Wuham;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V;Safety and tolerability of PHH-1V